查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574973

抗心律不整藥物市場，按藥物類別、按給藥途徑、按適應症、按配銷通路、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Antiarrhythmic Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年抗心律不整藥物市場規模為1,04,732萬美元，2024年至2032年複合年成長率為6.60%。

抗心律不整藥物市場-市場動態

心血管疾病盛行率上升推動抗心律不整藥物市場成長

心房顫動、心室性心律不整和心搏過速等心血管疾病 (CVD) 的盛行率不斷增加，推動了抗心律不整藥物的需求。在全球範圍內，世界衛生組織 (WHO) 等組織報告稱，CVD 仍然是死亡的主要原因，每年約有 1,790 萬人因此喪生。抗心律不整藥物在恢復正常心律和預防危及生命的併發症方面發揮著至關重要的作用。例如，胺碘酮和氟卡尼通常用於治療心律不整。各國政府和醫療保健提供者正致力於心律不整的早期診斷和治療，以降低與心血管疾病相關的死亡率，從而為抗心律不整藥物市場創造新的機會。此外，藥物配方的進步，例如更有針對性的治療，正在支持該領域的成長。

抗心律不整藥物市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 6.60% 左右的複合年成長率成長

根據藥物類別細分，鈉通道阻斷劑預計將在 2023 年顯示最大的市場佔有率

根據給藥途徑細分，2023年口服是領先類型

根據適應症細分，心房顫動是2023年的主導類型

按地區分類，北美是 2023 年的主要收入來源

抗心律不整藥物市場-細分分析：

全球抗心律不整藥物市場依據藥物類別、給藥途徑、適應症、配銷通路和地區進行細分。

依藥物類別，市場分為四類：鈉通道阻斷劑、BETA-阻斷劑、鉀通道阻斷劑、鈣通道阻斷劑。鈉通道阻斷劑由於廣泛用於治療心律不整而具有最高優先級，其次是鉀通道阻斷劑和BETA-阻斷劑，因其功效而聞名。相比之下，鈣通道阻斷劑排名較低。

根據給藥途徑，市場分為三類：口服、注射和經皮。由於方便和患者偏好，口服給藥具有最高優先級，其次是注射劑型以滿足更直接的治療需求。經皮給藥的使用率較低，但在某些情況下越來越受到關注。

抗心律不整藥物市場-地理洞察

抗心律不整藥物市場呈現出顯著的地理差異，由於心血管疾病的高盛行率和強大的醫療基礎設施，北美在 2023 年將處於領先地位。美國心臟協會報告稱，美國有近 270 至 610 萬人患有心房顫動，這是抗心律不整藥物需求的主要驅動力。歐洲緊隨其後，並得到歐洲心臟病學會 (ESC) 旨在加強心律不整管理和研究的計劃等計劃的支持。在亞太地區，快速的城市化和生活方式的改變增加了心血管疾病的風險，中國和印度等國家對抗心律不整治療的需求不斷成長。亞太地區也受益於旨在改善醫療保健可近性的政府計劃，例如印度的 Ayushman Bharat 計劃，該計劃專注於提供負擔得起的醫療服務。拉丁美洲、中東和非洲地區呈現溫和成長，醫療基礎設施投資不斷增加，人們對心臟病治療的認知不斷提高，刺激了這些地區對抗心律不整藥物的需求。

抗心律不整藥物市場-競爭格局：

抗心律不整藥物市場的競爭格局以活躍的活動為標誌，北美在創新和策略合作方面處於領先地位。例如，輝瑞（Pfizer）和安進（Amgen）等美國製藥巨頭一直處於開發先進抗心律不整治療的前沿。 2022年，輝瑞宣布與百時美施貴寶建立戰略合作關係，以擴大其心血管藥物組合，該藥物也針對心律不整。歐洲緊隨其後，賽諾菲和諾華等公司積極參與研究合作，以提高藥物療效和病患治療效果。最近，諾華在歐洲市場推出了一款旨在減少心房顫動復發的新藥，解決了重大未滿足的需求。亞太地區正迅速成為關鍵地區，武田製藥等地區企業對研發的投資不斷增加。 2023年，武田宣布與當地一家生技公司合併，以擴大其心血管藥物組合，這標誌著該地區抗心律不整藥物市場的競爭和創新加劇。

最新進展：

2024 年 5 月，Milestone Pharmaceuticals Inc. 與心律不整聯盟合作，提高人們對室上性心搏過速 (SVT) 的認知。此次合作旨在改善對該疾病的教育和了解，突顯 Milestone 對創新心血管治療的承諾。

2023 年 12 月，專注於心房顫動創新療法的生物技術公司 Acesion Pharma 宣佈在《Nature Medicine》上發表其突破性 SK 離子通道抑制劑 AP30663 的 2 期概念驗證試驗結果。

目錄

第1章：抗心律不整藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的抗心律不整藥物市場片段
    • 依給藥途徑分類的抗心律不整藥物市場片段
    • 以適應症分類的抗心律不整藥物市場片段
    • 按配銷通路分類的抗心律不整藥物市場片段
    • 按國家/地區分類的抗心律不整藥物市場片段
    • 按地區分類的抗心律不整藥物市場片段
  • 競爭洞察

第 3 章：抗心律不整藥物主要市場趨勢

  • 抗心律不整藥物市場促進因素
    • 市場促進因素的影響分析
  • 抗心律不整藥物市場限制
    • 市場限制影響分析
  • 抗心律不整藥物市場機會
  • 抗心律不整藥物市場未來趨勢

第 4 章：抗心律不整藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：抗心律不整藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：抗心律不整藥物市場格局

  • 2023 年抗心律不整藥物市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：抗心律不整藥物市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 鈉通道阻斷劑
    • BETA-受體阻斷劑
    • 鉀通道阻斷劑
    • 鈣通道阻斷劑

第 8 章：抗心律不整藥物市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 可注射
    • 經皮

第 9 章：抗心律不整藥物市場 - 按適應症

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 心房震顫
    • 室性心搏過速
    • 心室上性心搏過速
    • 其他

第 10 章：抗心律不整藥物市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 11 章：抗心律不整藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美抗心律不整藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按指標）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲抗心律不整藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模與預測（按指標）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區抗心律不整藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模與預測（依指標）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗心律不整藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模與預測（按指標）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲抗心律不整藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（依指標）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 抗心律不整藥物產業

  • 競爭儀表板
  • 公司簡介
    • Abbott Laboratories
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Harlan Laboratories, Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3966

REPORT HIGHLIGHT

Antiarrhythmic Drugs Market size was valued at USD 1,047.32 million in 2023, expanding at a CAGR of 6.60% from 2024 to 2032.

The Antiarrhythmic Drugs Market focuses on medications used to treat abnormal heart rhythms (arrhythmias), which are conditions where the heart beats irregularly, too fast, or too slow. These drugs are essential for preventing complications like stroke and heart failure. The increasing prevalence of cardiovascular diseases globally has been a significant growth factor, with atrial fibrillation affecting more than 33 million people worldwide. However, side effects associated with antiarrhythmic drugs and the availability of alternative treatments, such as catheter ablation, act as restraints. Opportunities lie in the development of new and safer antiarrhythmic drugs and the growing demand for minimally invasive treatments. Government health initiatives and rising geriatric populations further support market expansion, particularly in regions like North America and Europe.

Antiarrhythmic Drugs Market- Market Dynamics

Rising Prevalence of Cardiovascular Diseases Fuels Growth in the Antiarrhythmic Drugs Market

The increasing prevalence of cardiovascular diseases (CVDs), such as atrial fibrillation, ventricular arrhythmias, and tachycardia, is driving the demand for antiarrhythmic drugs. Globally, organizations like the World Health Organization (WHO) report that CVDs remain the leading cause of death, responsible for approximately 17.9 million lives annually. Antiarrhythmic drugs play a crucial role in restoring normal heart rhythm and preventing life-threatening complications. For example, Amiodarone and Flecainide are commonly prescribed to manage irregular heartbeats. Governments and healthcare providers are focusing on early diagnosis and treatment of arrhythmias to reduce CVD-related mortality, creating new opportunities in the antiarrhythmic drugs market. Additionally, advancements in drug formulations, such as more targeted therapies, are supporting growth in this sector.

Antiarrhythmic Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.60% over the forecast period (2024-2032)

Based on Drug Class segmentation, Sodium Channel Blockers was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Indication segmentation, Atrial Fibrillation was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Antiarrhythmic Drugs Market- Segmentation Analysis:

The Global Antiarrhythmic Drugs Market is segmented on the basis of Drug Class, Route of Administration, Indication, Distribution Channel, and Region.

The market is divided into four categories based on Drug Class: Sodium Channel Blockers, Beta-Blockers, Potassium Channel Blockers, and Calcium Channel Blockers. Sodium Channel Blockers held the highest priority due to their widespread use in managing arrhythmias, followed by Potassium Channel Blockers and Beta-Blockers, known for their efficacy. Calcium Channel Blockers ranked lower in comparison.

The market is divided into three categories based on the Route of Administration: Oral, Injectable, and Transdermal. Oral administration held the highest priority due to convenience and patient preference, followed by Injectable forms for more immediate treatment needs. Transdermal administration ranked lower in usage but is gaining interest for certain conditions.

Antiarrhythmic Drugs Market- Geographical Insights

The antiarrhythmic drugs market shows significant geographical variation, with North America leading in 2023 due to the high prevalence of cardiovascular diseases and robust healthcare infrastructure. The American Heart Association reports that nearly 2.7 to 6.1 million people in the U.S. suffer from atrial fibrillation, a key driver for antiarrhythmic drug demand. Europe follows closely, supported by initiatives such as the European Society of Cardiology's (ESC) programs to enhance arrhythmia management and research. In Asia-Pacific, rapid urbanization and lifestyle changes have increased the risk of cardiovascular diseases, with countries like China and India witnessing growing demand for antiarrhythmic treatments. The Asia-Pacific region is also benefiting from government programs aimed at improving healthcare access, such as India's Ayushman Bharat scheme, which focuses on providing affordable medical care. Latin America and the Middle East & Africa show moderate growth, with increasing investments in healthcare infrastructure and rising awareness about heart disease treatments fueling demand for antiarrhythmic drugs in these regions.

Antiarrhythmic Drugs Market- Competitive Landscape:

The competitive landscape of the antiarrhythmic drugs market is marked by significant activity, with North America leading in terms of innovation and strategic collaborations. For instance, U.S.-based pharmaceutical giants such as Pfizer and Amgen have been at the forefront of developing advanced antiarrhythmic treatments. In 2022, Pfizer announced a strategic partnership with Bristol-Myers Squibb to expand their portfolio of cardiovascular drugs, which also targets arrhythmias. Europe follows closely, with companies like Sanofi and Novartis actively engaging in research collaborations to improve drug efficacy and patient outcomes. Recently, Novartis launched a new drug in the European market aimed at reducing the recurrence of atrial fibrillation, addressing a significant unmet need. Asia-Pacific is rapidly emerging as a key region, with growing investments in R&D by regional players like Takeda Pharmaceuticals. In 2023, Takeda announced a merger with a local biotech firm to expand its portfolio of cardiovascular drugs, signaling increased competition and innovation in the region's antiarrhythmic drugs market.

Recent Developments:

In May 2024, Milestone Pharmaceuticals Inc. partnered with Arrhythmia Alliance to promote awareness of supraventricular tachycardia (SVT). This collaboration aims to improve education and understanding of the condition, highlighting Milestone's commitment to innovative cardiovascular treatments.

In December 2023, Acesion Pharma, a biotech firm focused on innovative therapies for atrial fibrillation, announced the publication of its Phase 2 proof-of-concept trial results for AP30663, a groundbreaking SK ion channel inhibitor, in Nature Medicine.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIARRHYTHMIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Harlan Laboratories, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Sodium Channel Blockers
  • Beta-Blockers
  • Potassium Channel Blockers
  • Calcium Channel Blockers

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Transdermal

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Atrial Fibrillation
  • Ventricular Tachycardia
  • Supraventricular Tachycardia
  • Other

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antiarrhythmic Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antiarrhythmic Drugs Market Snippet by Drug Class
    • 2.1.2. Antiarrhythmic Drugs Market Snippet by Route of Administration
    • 2.1.3. Antiarrhythmic Drugs Market Snippet by Indication
    • 2.1.4. Antiarrhythmic Drugs Market Snippet by Distribution Channel
    • 2.1.5. Antiarrhythmic Drugs Market Snippet by Country
    • 2.1.6. Antiarrhythmic Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Antiarrhythmic Drugs Key Market Trends

  • 3.1. Antiarrhythmic Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antiarrhythmic Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antiarrhythmic Drugs Market Opportunities
  • 3.4. Antiarrhythmic Drugs Market Future Trends

4. Antiarrhythmic Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antiarrhythmic Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antiarrhythmic Drugs Market Landscape

  • 6.1. Antiarrhythmic Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antiarrhythmic Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Sodium Channel Blockers
    • 7.1.3. Beta-Blockers
    • 7.1.4. Potassium Channel Blockers
    • 7.1.5. Calcium Channel Blockers

8. Antiarrhythmic Drugs Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable
    • 8.1.4. Transdermal

9. Antiarrhythmic Drugs Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Atrial Fibrillation
    • 9.1.3. Ventricular Tachycardia
    • 9.1.4. Supraventricular Tachycardia
    • 9.1.5. Other

10. Antiarrhythmic Drugs Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Antiarrhythmic Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Antiarrhythmic Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Antiarrhythmic Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Antiarrhythmic Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Antiarrhythmic Drugs Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Antiarrhythmic Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Antiarrhythmic Drugs Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Abbott Laboratories
    • 12.2.2. Amgen Inc.
    • 12.2.3. Astellas Pharma Inc.
    • 12.2.4. AstraZeneca PLC
    • 12.2.5. Bayer AG
    • 12.2.6. Boehringer Ingelheim GmbH
    • 12.2.7. Bristol-Myers Squibb Company
    • 12.2.8. Gilead Sciences, Inc.
    • 12.2.9. GlaxoSmithKline plc
    • 12.2.10. Harlan Laboratories, Inc.
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us